S
Seres Therapeutics, Inc. (MCRB)
NMS – Real vaqt narxi. Valyuta: USD
7.96
+0.01 (0.13%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
7.96
+0.01 (0.13%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Seres Therapeutics, Inc., klinik bosqichdagi kompaniya, jiddiy kasalliklar uchun bioterapevtik vositalarni ishlab chiqishga qaratilgan. Kompaniya SER-155ni ishlab chiqmoqda, bu oshqozon-ichak patogenlarini dekolonizatsiya qilish, oshqozon-ichak epiteliya to'siqlarining yaxlitligini oshirish va bakterial qon oqimi infektsiyalarini, shuningdek, allogenik gematopoez tayoqchalarini ko'chirib o'tkazishdan o'tgan bemorlarda patogenlar bilan bog'liq boshqa salbiy klinik natijalarni oldini olish uchun immunitet javobini tartibga solish uchun tadqiq qilinayotgan og'zaki tirik bioterapevtik vositadir. Shuningdek, u oshqozon-ichak mikrobiomining buzilishlarini davolash va yallig'lanishli bakteriyalar va ular bilan bog'liq metabolitlarni inhibe qilish orqali oshqozon-ichak shilliq qavatining yaxlitligini yaxshilash uchun optimallashtirilgan LBP nomzodi SER-603ni; va metabolik kasalliklar, shu jumladan surunkali jigar kasalliklari bo'lgan bemorlarda bakterial qon oqimi va spontan bakterial peritonit infektsiyalarini oldini olish uchun tirik bioterapevtik kompozitsiya SER-147ni ishlab chiqadi. Kompaniya avval Seres Health, Inc. nomi bilan tanilgan va 2015 yil may oyida Seres Therapeutics, Inc. deb o'zgartirgan. Seres Therapeutics, Inc. 2010 yilda tashkil etilgan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dennis M. Walling M.D. | Senior VP of Clinical Development & Head of Clinical Research |
| Dr. Matthew R. Henn Ph.D. | President & Chief Scientific Officer |
| Mr. Chris McChalicher | Executive VP & CTO |
| Mr. Richard N. Kender B.S., M.B.A. | Interim CEO & Executive Chair |
| Mr. Thomas J. DesRosier Esq., J.D. | Executive VP, Chief Legal Officer & Secretary |
| Ms. Ann Kurowski | Senior Vice President of Regulatory Affairs |
| Ms. Kelly Brady M.S. | Executive VP & COO |
| Ms. Marella Thorell CPA | Executive VP, CFO & Treasurer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | d155025d8k.htm |
| 2026-05-05 | 10-Q | mcrb-20260331.htm |
| 2026-04-27 | DEFA14A | ef20071345_defa14a.htm |
| 2026-03-16 | 8-K | d47103d8k.htm |
| 2026-03-12 | 10-K | mcrb-20251231.htm |
| 2026-03-02 | 8-K | d13425d8k.htm |
| 2025-11-05 | 8-K | d27174d8k.htm |
| 2025-11-05 | 10-Q | mcrb-20250930.htm |
| 2025-10-03 | 8-K | d63317d8k.htm |
| 2025-08-06 | 8-K | d930624d8k.htm |